GGrantIndex
← Leaderboards

Scott I. Abrams

Roswell Park Cancer Institute Corp

Google Scholar ↗PubMed ↗ORCID ↗
$11,133,748
Attributed
$18,613,627
Total exposure
12
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.4M · FY2011–25
$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,613,627 · 12

By mechanism

R01$16,321,023 · 7
R21$889,531 · 2
T32$852,837 · 1
P30$550,236 · 2

Top collaborators

Most similar at Roswell Park Cancer Institute Corp

Same institution · by research overlap

Others in their field

Top investigators on “Tumor”

Research focus

TumorCellsImmunotherapyMalignant NeoplasmsImmuneTumor MicroenvironmentMediatingResponseMolecularImmunityCytokineRecruitCancer ImmunotherapyT-LymphocyteNeoplastic CellMouse ModelGenesBasePublishingCd8-Positive T-LymphocytesTumor ImmunityLaboratoriesCancer CellImmune Response

Grant awards (45)

Determining the Impact of Metabolic Adaptations on the Immune-Tumor Microenvironment in Metastatic Breast Cancer$719,799
R01 · FY2025 · CA
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity$697,166
R01 · FY2025 · CA
Dissecting Molecular Mechanisms of Tumor-Induced Myeloid-Mediated Immune Suppression in Triple-Negative Breast Cancer$558,523
R01 · FY2025 · CA
Tumor Immunology and Immunotherapy$372,408
P30 · FY2025 · CA · contact PI
Multidisciplinary Approaches to Tumor Immunology$144,107
T32 · FY2025 · CA · contact PI
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry$1,124,755
R01 · FY2024 · CA
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity$662,308
R01 · FY2024 · CA
Dissecting Molecular Mechanisms of Tumor-Induced Myeloid-Mediated Immune Suppression in Triple-Negative Breast Cancer$571,496
R01 · FY2024 · CA
Identifying Chemo-Neoepitopes for Immunotherapy Interventions Against Triple-Negative Breast Cancer$460,977
R21 · FY2024 · CA
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines$359,516
R01 · FY2024 · CA
Multidisciplinary Approaches to Tumor Immunology$143,799
T32 · FY2024 · CA · contact PI
Tumor Immunology and Immunotherapy$44,983
P30 · FY2024 · CA · contact PI
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry$1,112,696
R01 · FY2023 · CA
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity$680,292
R01 · FY2023 · CA
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines$370,870
R01 · FY2023 · CA
Multidisciplinary Approaches to Tumor Immunology$144,099
T32 · FY2023 · CA · contact PI
Tumor Immunology and Immunotherapy$42,340
P30 · FY2023 · CA · contact PI
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry$993,003
R01 · FY2022 · CA
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity$694,227
R01 · FY2022 · CA
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines$370,870
R01 · FY2022 · CA
Development of a Novel Immunotherapy Platform for Triple-Negative Breast Cancer$192,653
R21 · FY2022 · CA
Multidisciplinary Approaches to Tumor Immunology$151,334
T32 · FY2022 · CA · contact PI
Tumor Immunology and Immunotherapy$44,540
P30 · FY2022 · CA · contact PI
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry$951,181
R01 · FY2021 · CA
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity$711,323
R01 · FY2021 · CA
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines$378,438
R01 · FY2021 · CA
Development of a Novel Immunotherapy Platform for Triple-Negative Breast Cancer$235,901
R21 · FY2021 · CA
Multidisciplinary Approaches to Tumor Immunology$135,457
T32 · FY2021 · CA · contact PI
Tumor Immunology and Immunotherapy$45,965
P30 · FY2021 · CA · contact PI
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry$994,901
R01 · FY2020 · CA
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines$393,352
R01 · FY2020 · CA
Multidisciplinary Approaches to Tumor Immunology$134,041
T32 · FY2020 · CA · contact PI
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages$389,411
R01 · FY2019 · CA · contact PI
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages$401,456
R01 · FY2018 · CA · contact PI
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages$401,456
R01 · FY2017 · CA · contact PI
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages$401,456
R01 · FY2016 · CA · contact PI
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages$401,456
R01 · FY2015 · CA · contact PI
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function$388,425
R01 · FY2015 · CA · contact PI
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function$54,171
R01 · FY2015 · CA · contact PI
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function$371,660
R01 · FY2014 · CA · contact PI
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function$52,545
R01 · FY2014 · CA · contact PI
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function$17,593
R01 · FY2014 · CA · contact PI
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function$355,357
R01 · FY2013 · CA · contact PI
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function$373,072
R01 · FY2012 · CA · contact PI
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function$368,249
R01 · FY2011 · CA · contact PI